Xintela appoints Lucienne Vonk as Chief Scientific Officer

Xintela announces that Lucienne Vonk, previously Director Musculoskeletal Diseases at Xintela, has been appointed Chief Scientific Officer. She takes over the role from the CEO Evy Lundgren-Åkerlund. “Lucienne Vonk joined Xintela about 1,5 years ago and has already made a great contribution to the development of our stem cell product XSTEM. Lucienne has extensive experience […]

Xintela newsletter, No. 1 2024

Read Xintela’s newsletter in English here. Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company’s cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain […]

First patient dosed in Xintela’s clinical study on difficult-to-heal leg ulcers

Xintela announces that the first patient has been dosed in the company’s clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg ulcers. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Xintela’s ongoing Phase I/IIa clinical study in patients with difficult-to-heal venous leg ulcers […]

Xintela publishes efficacy results with EQSTEM from preclinical equine OA study

The results from Xintela’s preclinical EQSTEM® study in horses with post-traumatic osteoarthritis (OA) have been published in the scientific journal Cartilage. The results demonstrate less pain and less cartilage damage after treatment with the stem cell product EQSTEM, indicating a disease modifying effect of EQSTEM. Xintela has previously published that integrin α10β1-selected stem cells from […]

Västra Hamnen Corporate Finance initiates coverage of Xintela

Xintela has entered into an agreement regarding commissioned equity research with Västra Hamnen Corporate Finance AB. The analysis includes a review of the company, its products, markets and competitors, as well as a financial scenario that forms the basis for an overall assessment of the company’s justified market capitalisation. Västra Hamnen will monitor the development […]

Xintela changes Certified Adviser to Carnegie Investment Bank AB (publ)

Xintela today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ). Xintela has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik […]

Xintela AB Interim Report January – September 2023

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter 2023 for the groupIncome amounted to TSEK 0 (0).Loss before tax totalled TSEK 11,953 (loss: 14,456).Loss per share was SEK 0.02 (loss: 0.11). First nine month 2023 for the groupIncome amounted to TSEK 0 (0).Loss before […]

Xintela’s stem cell product, XSTEM, has been assessed as safe at all dose levels in knee osteoarthritis clinical study

Xintela’s first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing three different dose levels of the stem cell product XSTEM®. The Safety Review Committee for the clinical study has now assessed all three dose levels safe at the planned three-month follow-up. XSTEM, which consists of allogeneic (donated) integrin […]

Xintela AB Interim Report January – June 2023

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Second quarter 2023 for the groupIncome amounted to TSEK 0 (0).Loss before and tax totalled TSEK 18,401 (loss: 18,942).Loss per share* was SEK 0.06 (loss: 0.21). First half year 2023 for the groupIncome amounted to TSEK 0 (0).Loss before […]

Xintela gets product patent in USA for chondrocyte-based products

Xintela today announces that the US Patent and Trademark Office (USPTO) has issued the company’s patent application on chondrocyte-based cell therapy products, with validity through 2039. Xintela’s US patent, US 11, 725,188, protects the development and commercialization of chondrocyte-based products that are quality assured using the cell surface markers integrin α10β1 and integrin α11β1. The […]